Yuka Ikenaga

ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder

A. Serretti, L. Mandelli, T. Kinoshita, 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population.

J. Azuma, T. Fukuda, S. Fukuen, 2002, Pharmacogenetics.

The frequency of candidate alleles for CYP2D6 genotyping in the Japanese population with an additional respect to the -1584C to G substitution.

J. Azuma, T. Fukuda, Y. Ikenaga, 2005, Drug metabolism and pharmacokinetics.

Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist

M. Tsuda, Keiichirou Ogawa, Akihito Ogasawara, 2023, European Journal of Clinical Pharmacology.

Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients

T. Kinoshita, G. Okugawa, J. Azuma, 2006, Neuropsychobiology.

The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.

S. Kiuchi, Yoshinobu Nakamaru, K. Ueta, 2015, Journal of pharmacological sciences.

CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers

J. Azuma, T. Fukuda, S. Fukuen, 2004, The Pharmacogenomics Journal.

Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism

T. Kinoshita, G. Okugawa, J. Azuma, 2005, International clinical psychopharmacology.